+ cells, while GM-CSF reduced the expression of CD62L. SCF was the only cytokine able to induce a significant increase of CD34 + cell adherence to preformed stroma. Pre-incubation with the blocking ␤2 integrin monoclonal antibody caused a reduction of CD34 + cell adherence. In conclusion, the decrease of CD49d expression on mobilized CD34
+ cells, while GM-CSF reduced the expression of CD62L. SCF was the only cytokine able to induce a significant increase of CD34 + cell adherence to preformed stroma. Pre-incubation with the blocking ␤2 integrin monoclonal antibody caused a reduction of CD34 + cell adherence. In conclusion, the decrease of CD49d expression on mobilized CD34
+ cells correlates with a poor adhesion to BM stroma; CD34
+ cells incubated in vitro with SCF showed, conversely, a higher expression of CD49d and a greater adherence capacity on normal preformed stroma. Keywords: CD34 + cells; adhesion molecules; normal donors; G-CSF Correspondence: Dr R Bellucci, Institute of Haematology, Via Benevento 6, 00161, Rome, Italy Received 24 September 1997; accepted 11 August 1998 CD34 identifies the progenitor cell population capable of reconstituting lethally irradiated animals or humans treated with myeloablative therapy. CD34
+ cells normally circulate in very low numbers, but the ability of recombinant haematopoietic growth factors to mobilise progenitor cells 1,2 has increased their use for both autologous and allogeneic transplantation procedures. Little is known of the mechanisms of mobilisation of normal and malignant cells, or of the role of adhesive interactions between primitive haematopoietic cells and marrow stromal cells. It is now clear that adhesion of haematopoietic cells to stromal elements is mediated by a number of adhesion molecules of the ␤1 3-5 and ␤2 integrin 6 family, as well as the L-selectins. 7 These include the ␤1-integrin very late antigen-4 (VLA-4, ␣4␤1-integrin, CD49d/CD29) and the ␤2-integrin leukocyte function-associated molecule-1 (LFA-1, ␣L␤2-integrin, CD11a/CD18). A critical role for the initial, reversible binding of the progenitors to the bone marrow (BM) stroma is also mediated by the L-selectins 8 and by the vascular and intercellular adhesion molecules (VCAM-1 for VLA-4 and ICAM-1 for LFA-1) which correspond to the binding sites on endothelial cells. 9, 10 Several authors have demonstrated that CD34 + cells mobilised by a variety of regimens and/or cytokines show a reduced expression of some adhesion molecules and a consequent modification of adhesion capacity to BM stroma; [11] [12] [13] it is not completely clear whether functional changes of CD34 + cells during mobilisation occur with those adhesion molecules which do not significantly change their expression on mobilised progenitor cells and whether different growth factors induce the same pattern of phenotypic and functional modifications as G-CSF. The coexpression of the ␤2 integrin LFA-1 and CD33 on CD34 + cells has been recently investigated, 14 and it has been suggested that the expression of LFA-1 may distinguish two subpopulations within CD34 + /CD33 Ϫ cells. Other studies have addressed the possibility that adhesion molecules may be expressed at different stages of progenitor cell differentiation, 15 although the large number of antigens to be considered and the variety of adhesion molecules expressed during progenitor cell differentiation make these studies difficult to interpret.
In the present study, we have analysed the immunophenotype and the clonogenic potential of peripheral blood (PB) CD34
+ cells from normal donors in steady-state conditions and after mobilisation with G-CSF. The adhesion molecules which showed a significant downregulation on CD34
+ cells during G-CSF administration were also studied according to the CD13 and c-kit expression. Functional experiments investigating the stem cell adherence capacity before and after G-CSF in vivo or after incubation with several growth factors in vitro were also conducted in an attempt to correlate changes in adhesion molecule expression with stem cell release from BM.
Materials and methods

Cell sources
PB samples were collected from a total of 25 healthy donors before and after mobilisation with recombinant granulocyte colony-stimulating factor (G-CSF, Granocyte, Rhone Poulenc Cedex, France). Of these, 20 were used to study the immunophenotype of CD34
+ cells before and after administration of G-CSF, while CD34
+ cells from five donors were utilised for the functional assays. Buffy coats from 11 further donors in steady-state were used for in vitro incubation with different growth factors or for the blocking experiments using adhesion molecule-specific monoclonal antibodies (MoAbs). G-CSF was administered subcutaneously at 5 or 10 g/kg. Cells were analysed in steady-state and on day 4 and day 6 of G-CSF administration. No significant differences were found in the number of WBC, CD34
+ cells, CFU-GM, BFU-E and CFU-Mix mobilised in PB following administration of either 5 or 10 g/kg of G-CSF. The data presented include, therefore, all samples.
BM cells were obtained from 11 healthy adult donors of allogenic bone marrow transplantation by multiple aspirations from the posterior iliac crests.
Informed consent for using cells in these studies was obtained from all the subjects.
Labelling cells for flow cytometry
CD34
+ cells were enumerated in unseparated PB, following incubation of 3 × 10 5 cells with FITC-conjugated anti-CD34 (HPCA-2; Becton Dickinson, San Jose, CA, USA) MoAb according to published methods. 16 For two-colour fluorescence analysis, mononuclear cells (MNC) were isolated by density gradient (1.077 g/ml) using FicollLymphoprep (Nycomed, Oslo, Norway) and suspended in 80-100 l of phosphate-buffered saline (PBS) containing 0.1% sodium azide (PBS-NaN 3 ). Cells were incubated for 30 min at 4°C with FITC or PE-conjugated anti-CD34 MoAb (BD) and one of the following PE or 
Flow cytometry
Flow cytometry was performed on a FACScan (BD) equipped with a 15 mW air-cooled argon-ion laser tuned at 488 nm. For single-colour analysis, a minimum of 14 000 cells was acquired for each measurement; for two-and three-colour analysis, minima of 500 CD34
+ cells for the steady-state PB and 2500 CD34
+ for all the other samples were acquired according to their fluorescence intensity and their low side scatter characteristics (SSC). The mean fluorescence intensity (MFI) was determined by comparing the fluorescence intensity of the test monoclonal antibody with that of isotype control stained cells. The four dimensional data were analysed using Lysis (BD) or FlowMate (Dako) softwares.
Stromal cell cultures
To prepare marrow stromal layers, 2 × 10 6 light density cells/ml in 9 ml were seeded per 25-cm 2 tissue culture flasks (Falcon, Labware, Meylan, France) in McCoy's 5A culture medium (GIBCO BRL, Paisley, UK) with 12.5% FCS, 12.5% horse serum and 10 Ϫ5 m hydrocortisone sodium succinate. Half of the medium was removed weekly and the adherent cells were passaged at least twice to eliminate haematopoietic cells before seeding 2 × 10 5 irradiated cells into 24-well plates 1 week before the binding experiment, to allow the formation of an adequate marrow stroma.
Adhesion assay
To investigate whether the binding capacity of normal CD34 + cells to marrow stroma is modified after incubation with different growth factors (GF), we evaluated the number of CD34 + cells adherent per stromal cell, after incubation for 5 days with serum-free medium (SFM) (StemPro; GIBCO BRL, Grand Island, NY, USA), or SFM supplemented with one of the following growth factor: G-CSF, GM-CSF, IL-3 or stem cell factor (SCF) (20 ng/ml each). Buffy coat samples from eight normal volunteer donors were separated by Ficoll-Hypaque centrifugation, followed by Percoll density gradient (1.065 g/ml). CD34 + cells were enriched using the MACS CD34 Isolation Kit (Miltenyi Biotec, Sunnyvale, CA, USA), according to the manufacturer's instructions as previously described. The proportion of CD34 + cells in the enriched fraction ranged in the eight samples from 65 to 90%.
Before and after 5 days incubation with the different GF, an aliquot was stained with the anti-CD34-PE and one of the following adhesion molecules: anti-CD49d, anti-CD62L, anti-CD11a as described above; an aliquot (1 × 10 5
CD34
+ enriched cells) was resuspended in cold SFM and added to previously prepared feeder layer in 24-well plates.
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+ cells R Bellucci et al 3 After 90 min incubation at 37°C, the supernatant that contained the nonadherent cells was removed and the layer was washed with PBS. The layers of stromal cells with the adherent CD34 + cells were trypsinised and the proportion of stromal cells and CD34
+ cells, as well as the number of CD34
+ cells adherent per stromal cell was measured by direct immunofluorescence analysis, as previously described. 13 To Ϫ5 mol/l 2-mercaptoethanol, 2 mm l-glutamine, 0.5 U/ml penicillin, 0.5 g/ml streptomycin, 20 ng/ml IL-3 (Sandoz Pharma, Basel, Switzerland), 5 ng/ml GM-CSF (Sandoz Pharma) and 5 IU/ml erythropoietin (Eprex, epoetine alfa, Cilag, Schaffhausen, Switzerland). After 10-14 days of incubation at 37°C and 5% CO 2 in air, colonies (Ͼ40 cells) derived from granulocyte-macrophage colony-forming units (CFU-GM), erythroid burst-forming units (BFU-E) and mixed granuloerythropoietic colony-forming units (CFU-MIX) were assessed according to established criteria 17 and counted using an inverted microscope. Long-term culture-initiating cells (LTC-IC) were enumerated according to published methods. 18 Briefly, 5 × 10 5 mononuclear cells were plated by limiting dilution in contact with irradiated stromal layer of M2-10B4 cells, kindly provided by Dr C Eaves (Vancouver, BC, Canada) and maintained for 5 weeks at 37°C and 5% CO 2 , removing weekly half of the supernatant and replacing it with fresh LTC medium. After 5 weeks, all media were removed and the feeders overlaid with methylcellulose supplemented with EPO (3 IU/ml) and 10% supernatant of the 5637 cell line. The absolute number of LTC-IC was calculated using Poisson's statistics.
Statistical analysis
Multiple group comparison was performed using analysis of variance (ANOVA) or Friedman test. Two-group comparison was based on Student's t-test. The number of LTC-IC before and after administration of G-CSF was calculated using Poisson's analysis. A P value Ͻ0.05 was considered statistically significant.
Results
Enumeration of CD34 + cells in normal PB before and after 4 and 6 days of G-CSF
CD34
+ cells were enumerated in the PB of 20 normal donors in the CD34 vs SSC dot plot. The median proportion of CD34
+ cells in the PB in steady-state was 0.06% (range 0.001-0.13). G-CSF administration increased the proportion of CD34 + cells to a median of 0.16% (range 0.06-0.51) on day +4 and to 0.15% (range 0.08-0.99) on day +6, respectively. In parallel, the absolute number of CD34 + cells/l increased from a median of 4.5/l (range 0.34-9.4) before starting G-CSF to 42.5/l (range 15.6-141.8) on day +4 (P Ͻ 0.0001) and to 53.1/l (range 16.5-182.2) on day +6. Although a significant difference was found between the value of CD34
+ cells found on day 0 and on day 4, no differences were found between day 4 and day 6 of G-CSF. The MFI evaluated for all samples on the histogram of FITC-conjugated CD34
+ cells showed no significant differences between the values found on day 0 (5.2 Ϯ 0.2), day 4 (4.2 Ϯ 0.2) and day 6 (4.5 Ϯ 0.4), respectively.
Phenotype of CD34
+ cells Table 1 reports the proportion of CD34 + cells expressing lineage-specific or differentiating antigens. Among the antigens evaluated on CD34
+ cells (HLA-DR, CD38, CD13, CD33, c-kit and Thy-1), only the expression of c-kit varied significantly from day 0 to day 4 and day 6 at the double fluorescence analysis. However, because of the absence of a well-defined c-kit + and c-kit Ϫ population, but rather of the presence of a continuous intensity of expression from very low to intermediate levels, the definition of CD34 + /ckit + cells on day 0 could have been arbitrarily set; nonetheless, the proportion of c-kit + cells on day 4 and day 6 of G-CSF administration was significantly lower compared to the steady-state level. No differences were found in the MFI before and after G-CSF for all antigens evaluated. Three-colour fluorescence analysis using FITC-conjugated anti-CD34, PE-conjugated anti-CD13 and PerCp-conjugated anti-HLA-DR MoAb showed a different distribution of CD34
+ cell subpopulations, related to the different days of G-CSF administration. In six normal donors studied in steady-state and after 4 and 6 days of G-CSF, evaluation of CD34 + subpopulations indicated a progressive increase of the more differentiated CD34 
Expression of adhesion molecules on PB CD34 + cells
To investigate the modulation of adhesion molecules on CD34 + cells before and after G-CSF administration, the expression of the ␤1 integrins CD49b and VLA-4 (CD49d), the ligand of LFA-1 ICAM-1 (CD54), the ␤2 integrins CD11a and CD18, and the L-selectin CD62L was examined in a double-colour assay with PE-conjugated CD34 MoAb on PB in steady-state and on mobilised (days 4 and 6) CD34
+ cells. Table 2 shows the proportion of doublepositive cells found on the different days of G-CSF
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+ cells R Bellucci et al 4 administration. The expression of CD49b and CD54 did not vary among the days of evaluation in the 20 normal donors evaluated. On the contrary, the expression of CD11a, CD18, CD49d and CD62L significantly decreased from day 0 to day 4 and day 6 of G-CSF. No differences were found in the MFI of each molecule studied. To evaluate the modulation of VLA-4 and CD62L on CD34 + subpopulations according to the different days of G-CSF administration, three-colour fluorescence analysis was conducted in six normal donors using PerCp anti-CD34, FITC anti-CD49d or anti-CD62L and PE anti-CD13 or anti-CD117 (c-kit). The overall expression of CD49d and CD62L on CD34 + cells decreased from the steady-state level after day 4 and day 6 of G-CSF treatment, confirming the data found in double fluorescence analysis. However, 50 and 42% of CD34 + /CD49d + and CD34 + /CD62L + , respectively, coexpressed CD13, while 13 and 6% of the same subpopulations did not express CD13 before initiating G-CSF. Interestingly, a different pattern of expression of the two adhesion molecules was found during CD34 + cell differentiation by G-CSF: the decrease of CD49d on CD34 + cells was found almost exclusively within CD13 + cells, while the reduction of CD62L on CD34 + cells was seen within both CD13 + and CD13 Ϫ cell subpopulations (Figure 1) . Conversely, the expression of CD49d and CD62L on c-kit + /c-kit Ϫ cells was different from that observed on CD13 + /CD13 Ϫ cells. The majority of CD49d + and CD62L + cells were expressed within c-kit Ϫ cells before G-CSF; the expression of CD49d during G-CSF decreased on both c-kit + and c-kit Ϫ cells, while the expression of CD62L decreased almost exclusively on c-kit + cells (Figure 2 ). In six normal BM allogeneic transplantation donors, we evaluated the expression of CD49d and CD62L on CD34 expression of BM CD62L was lower than that of PB in steady-state. Three-colour fluorescence analysis showed that the expression of BM CD49d was lower than that of PB on the CD13 + fraction (39 vs 50%) and higher on the CD13 Ϫ fraction (27 vs 13%). The expression of BM CD62L was lower than that of PB in both the CD13 + and CD13
Ϫ subpopulations (23 vs 42% and 3 vs 6%, respectively).
In vivo G-CSF administration reduces PB CD34
+ cell adherence to BM stroma
To verify that the downregulation of adhesion molecules on CD34
+ cells after in vivo administration of G-CSF may also reflect a functional aspect during stem cell release from human BM, CD34
+ cells obtained from PB of normal donors after 5 days administration of G-CSF were layered over normal BM stroma and the adherence capacity was compared to that of normal BM cells and steady-state PB. In a total of five experiments, the number of PB CD34 
Modulation of VLA-4, L-selectin and ␤2-integrin on PB CD34 + cells after in vitro incubation with different cytokines
To evaluate whether the downregulation of adhesion molecules on CD34
+ cells was specifically induced by G-CSF or similarly produced by other growth factors, in eight experiments the proportion of normal PB CD34 + cells expressing CD49d, CD62L or CD11a was evaluated after 5 days in vitro incubation in SFM, or SFM supplemented with G-CSF, GM-CSF, IL-3 or stem cell factor (SCF). A similar proportion of CD34 + /CD49d + , CD34 + /CD62L + , or CD34 + /CD11a + was found after 5 days incubation in SFM + G-CSF, compared to SFM only. However, a significantly greater expression of CD49d on CD34
+ cells was observed after incubation with SCF (P = 0.018) or IL-3 (P = 0.004), while a reduced expression of CD62L was found after incubation with GM-CSF (P = 0.007). A similar proportion of CD34 + /CD11a + was identified after incubation with G-CSF, GM-CSF, IL-3 or SCF (Table 3) .
SCF enhances normal PB CD34
+ cell adhesion to human stroma
After exposure of enriched normal CD34
+ cells to the different cytokines for 5 days, an equal number of CD34 + cells was subsequently cocultured with IL-1␤ pre-incubated human stroma. The effect of G-CSF, GM-CSF, IL-3 or SCF on the adhesion of CD34 + cells was evaluated enumerating the number of CD34 + adherent cells per stromal cell after 90 min incubation. Compared to the number of adherent CD34 + cells after incubation in SFM for 5 days, a range between 0.7 and 1.8, 0.7 and 1.2, 0.8 and 1.4 and 1.7 and 4.6-fold of adherence was found after 5 days incubation with G-CSF, GM-CSF, IL-3 and SCF, respectively ( Figure  4 ). The number of CD34 + cells adherent per stromal cell after incubation with SCF was 3.41 Ϯ 1.05-fold compared to the number of cells adherent after incubation with SFM and was significantly higher (P Ͻ 0.05) compared to the number of adherent CD34 + cells found after incubation with any other growth factor. In a series of three experiments, the adhesion of CD34 + cells was evaluated following preincubation with the blocking ␤1-integrin (CD49d), L-selectin (CD62L) and ␤2-integrin (CD11a) MoAbs. In general, the blocking MoAb against L-selectin and ␤1-integrin did not interfere with the adhesion of CD34 + cells to the stromal layer. After incubation of CD34 + cells in SFM for 5 days, we found that CD34
+ cells pre-incubated with the blocking 
G-CSF significantly increased erythroid, myeloid and multipotent progenitors in PB
Evaluation of CFU-GM, BFU-E, CFU-MIX and LTC-IC in the PB in steady-state, calculated as the number of colonies/ml or colonies/CD34
+ cell, showed, in the normal donors tested, a mean of 220.4 CFU-GM/ml, 320.8 BFU-E/ml, 21.15 CFU-MIX/ml and 15.1 LTC-IC/ml. Administration of G-CSF for 4 days caused a significant increase in the clonogenic capacity of all the progenitors evaluated. As shown in Table 4 , CFU-GM, BFU-E, CFU-MIX and LTC-IC significantly increased from the steady-state level to day 4 or to day 6 of G-CSF; however, only CFU-GM showed a significant increase from day 4 to day 6 of G-CSF.
Discussion
In this study, we evaluated the phenotypic expression, functional activity and clonogenic potential of CD34 + cells in Table 4 Growth of granulocyte-macrophage, erythroid, mixed and LTC-IC before and after G-CSF administration the PB of 20 normal donors in steady-state and after G-CSF administration. As expected, G-CSF caused an expansion of the progenitor cell compartment both in terms of the absolute number of CD34 + cells and of the number of pluripotent and more differentiated progenitors. 18 The lineage-associated and activation antigens tested on CD34 + cells showed no significant differences between the steadystate and days 4 or 6 of G-CSF treatment, with the exception of the proportion of CD34 + cells expressing the stem cell factor receptor (c-kit). The observation that in mobilised PB the expression of c-kit is markedly reduced on CD34 + cells has been recently reported, 19 although the mechanisms responsible for this reduction remain unknown. Certainly, the interaction between the stem cell factor and its receptor (c-kit) may influence some function of the progenitor cells and the loss of the c-kit receptor on CD34
+ cells could produce a reduced ability to mobilise, as described in animals. 20 Several reports have considered the expression and the variation of lineage-specific and activation antigens on CD34
+ cells during mobilisation with G-CSF. Along with some well established results, discrepancies arise when other factors are taken into consideration such as mobilisation regimens, timing of apheresis, the nature of haemopoietic disorder and types of antigens evaluated. In our study, we used cells from normal donors admitted to a program of G-CSF mobilisation and normal donors of allogeneic bone marrow. A 13-and 17-fold increase in the number of PB CD34 + cells/l was seen on days 4 and 6 of G-CSF compared to steady-state; it is therefore clear that the increase in the absolute number of some CD34
+ cell subpopulations reported after G-CSF administration reflects the large expansion of progenitor cells, rather than the specific effect on a single cell fraction. In general, a similar proportion of CD34 + cell subpopulations has been found before and after G-CSF, both in terms of percentage of positive cells and of MFI. In particular, the variation found by several authors in the expression of Thy-1 on CD34
+ cells and the dependence of the proportion of CD34 + /Thy-1 + cells on the day of leukapheresis [21] [22] [23] was not confirmed in our study, which indicates a low and stable expression of Thy-1 on PB CD34
+ cells before and after G-CSF, but a higher proportion of CD34 In this study, several adhesion molecules likely to be involved in the mobilization processes have been tested on haematopoietic progenitors at different days of G-CSF treatment. The expression of ICAM-1 (CD54) and of the ␤1 integrin CD49b did not vary between the steady-state and days 4 and 6 of G-CSF administration. Conversely, a significant decrease of CD11a, CD18, CD49d and CD62L on CD34
+ cells between day 0 and day 4 was found. In addition, the last two antigens showed a further significant reduction on CD34
+ cells between day 4 and day 6 of G-CSF. Several studies have suggested that among the many families of adhesion molecules, the ␤1 integrin VLA-4 and L-selectin are probably the most involved in the stem cell adhesion to extracellular matrix and that alterations in the expression of VLA-4 may result in the egress from BM of a large number of haematopoietic progenitors. In vivo, animal studies have recently confirmed the prominent role of VLA-4 in the adhesion of haematopoietic progenitors to the marrow stroma by pre-incubation of transplanted marrow cells with antibodies to VLA-4 or in vivo administration of an adhesion-blocking anti-VLA-4 which led to a dramatic mobilization of clonogenic cells into the peripheral blood. 24, 25 In functional assays, the CD34 + cell compartment exposed in vivo to 5 days administration of G-CSF showed a decreased expression of VLA-4, L-selectin and LFA-1 and a reduced adherence to stromal cells, compared to the steady-state PB. Conversely, the greater coexpression of adhesion molecules on BM CD34
+ cells and the different distribution of VLA-4 and L-selectin on the BM CD34 + subpopulation correlated with a greater adherence capacity of CD34 + BM cells, compared to both steady-state and G-CSF mobilised PB. Furthermore, we investigated whether the change in the immunophenotype and in the adherence capacity of CD34 + cells observed during stem cell mobilisation in vivo could be specifically induced by G-CSF, or similarly caused by other GF in in vitro experimental models. The expression of VLA-4 and L-selectin on CD34 + cells did not vary after in vitro incubation for 5 days with G-CSF; on the contrary, 5 days incubation with IL-3 and SCF led to a significant increase in the proportion of CD34 + cells expressing VLA-4 and/or L-selectin. The functional experiments conducted with CD34 + cells incubated for 5 days with SFM or SFM supplemented with G-CSF, GM-CSF, IL-3 or SCF, showed no variation in the adherence capacity of CD34 + cells to BM stroma after incubation with G-CSF, GM-CSF and IL-3, but a significantly greater proportion of CD34 + adherent cells after 5 days incubation with SCF. In general, a different pattern of adhesion molecule expression on CD34 + cells cultured in vitro and a different behaviour of CD34 + cells in the functional assays was observed compared to CD34 + cells mobilised in vivo. This indicates that the complexity of this system, which reflects the heterogeneity within the haemopoietic cell population, the variety of cellular and extracellular matrix elements and the mechanisms by which the stromal adhesion is initiated and stabilised, needs more sensitive methods to identify the various adhesion pathways which may be involved.
It is likely that adhesion molecules or activation antigens other than those reported here are of importance in the mobilisation of progenitor cells and in vivo experimental studies in animals and in humans are expected to produce major contributions in the understanding of cellular trafficking.
